Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2008-07-01
2008-07-01
Gabel, Gailene R (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S003000, C435S004000, C435S006120, C435S007230, C435S007240, C435S040510, C435S375000, C435S287200, C435S973000, C436S546000, C436S010000, C436S056000, C436S063000, C436S064000, C436S172000, C436S174000
Reexamination Certificate
active
10898734
ABSTRACT:
The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.
REFERENCES:
patent: 4979824 (1990-12-01), Mathies et al.
patent: 5137809 (1992-08-01), Loken et al.
patent: 5919646 (1999-07-01), Okun et al.
patent: 5968738 (1999-10-01), Anderson et al.
patent: 6280967 (2001-08-01), Ransom et al.
patent: 6379917 (2002-04-01), Okun et al.
patent: 6558916 (2003-05-01), Veerapandian et al.
patent: 6673554 (2004-01-01), Kauvar
patent: 6821740 (2004-11-01), Darzynkiewicz et al.
patent: 6958221 (2005-10-01), Veerapandian et al.
patent: 2002/0127604 (2002-09-01), Albritton et al.
patent: 2002/0197658 (2002-12-01), Delaney et al.
patent: 2003/0190688 (2003-10-01), Crosby et al.
patent: 2003/0190689 (2003-10-01), Crosby et al.
patent: 2003/0219827 (2003-11-01), Comb et al.
patent: 2004/0063088 (2004-04-01), Berg et al.
patent: 2004/0072164 (2004-04-01), Yoganathan et al.
patent: 2004/0106156 (2004-06-01), Perez et al.
patent: 2004/0126784 (2004-07-01), Hitoshi et al.
patent: 2004/0137539 (2004-07-01), Bradford
patent: 2004/0170995 (2004-09-01), Lograsso et al.
patent: 2004/0180380 (2004-09-01), Lee et al.
patent: 2004/0219592 (2004-11-01), Berg et al.
patent: 2004/0224371 (2004-11-01), DeMatos et al.
patent: 2004/0229284 (2004-11-01), Luciw et al.
patent: 2004/0241636 (2004-12-01), Michnick et al.
patent: 2004/0248151 (2004-12-01), Bacus et al.
patent: 2005/0009112 (2005-01-01), Edgar et al.
patent: 2005/0042694 (2005-02-01), Darzynkiewicz et al.
patent: 2005/0074834 (2005-04-01), Chaplen et al.
patent: 2005/0084924 (2005-04-01), Shults et al.
patent: 2005/0131006 (2005-06-01), Mukherjee et al.
patent: 2005/0216961 (2005-09-01), Delaney
patent: 2005/0250127 (2005-11-01), Fisher et al.
patent: 2005/0281743 (2005-12-01), Delaney
patent: 2006/0029944 (2006-02-01), Huang et al.
patent: 2006/0035211 (2006-02-01), Levinson et al.
patent: 2006/0040338 (2006-02-01), Westwick et al.
patent: 2006/0046249 (2006-03-01), Huang et al.
patent: 2006/0073474 (2006-04-01), Perez et al.
patent: WO 03/067210 (2003-08-01), None
Chow et al., Measurement of MAP Kinase Activation in Flow Cytometry Using Phospho-Specific Antibodies to MEK and ERK: Potential for Pharmacodynamic Monitoring of Signal Transduction Inhibitors, Cytometry (Comms. in Clinical Cytometry) 46: 72-78 (May 2001).
Perez et al. “LFA-1 Signaling Through p44/42 is Coupled to Perform Degranulation in CD56+CD8+Natural Killer Cells,” Blood (2004) 104(4):1083-1093.
Irish et al. “Single Cell Profiling of Potentiated Phospho-Protein Networks in Cancer Cells,” Cell (2004) 118:217-228.
Krutzik et al. “Analysis of Protein Phosphorylation and Cellular Signaling Events by Flow Cytometry: Techniques and Clinical Applications,” Clinical Immunology (2004) 110:206-221.
Perez, Omar; et al., “Methods for the simultaneous determination of the activation state of multiple proteins”, U.S. Appl. No. 60/304,434, filed Jul. 10, 2001.
Nolan, Garry; et al., “Methods for determining kinase activity”, U.S. Appl. No. 60/310,141, filed Aug. 2, 2001.
Perez OD, Mitchell D, Jager GC, South S, Murriel C, McBride J, Herzenberg LA, Kinoshita S, Nolan GP. Leukocyte functional antigen 1 lowers T cell activation thresholds and signaling through cytohesin-1 and Jun-activating binding protein 1. Nature Immunology. Nov. 2003;4(11):1083-92.
Morgan et al., “Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling”, Neoplasia, Mar. 15, 2001, vol. 97, No. 6, pp. 1823-1834.
Allende, L. M., et al., (2000). “A novel CD18 genomic deletion in a patient with severe leucocyte adhesion deficiency: a possible CD2/lymphocyte function-associated antigen-1 functional association in humans.”Immunology99:440-50.
Anderson, M.T. et al. (1996). “Simultaneous fluorescence-activated cell sorter analysis of two distinct transcriptional elements within a single cell using engineered green fluorescent proteins,”Proc Natl Acad Sci U S A93, 8508-11.
Bleijs, D. A., et al. (2001). “A single amino acid in the cytoplasmic domain of the beta 2 integrin lymphocyte function-associated antigen-1 regulates avidity-dependent inside-out signaling.”J Biol Chem276, 10338-10346.
Colucci, F., et al. (1999). “Redundant role of the Syk protein tyrosine kinase in mouse NK cell differentiation.”J Immunol163, 1769-1774.
Damle, N. K., et al. (1992c). “Differential regulatory effects of intercellular adhesion molecule-1 on constimulation by the CD28 counter-receptor B7.”J Immunol149, 2541-2548.
Dantuma, N. P., et al. “Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells.”Nat Biotechnol18, 538-43. (2000).
Davis, K. A., et al., (1998). “Determination of CD4 antigen density on cells: role of antibody valency, avidity, clones, and conjugation.”Cytometry33, 197-205.
De Fougerolles, A. R., et al. (1995). “Heterogenous glycosylation of ICAM-3 and lack of interaction with Mac-1 and p150,95.”Eur J Immunol25, 1008-12.
De Fougerolles, et al. (1991). “Characterization of ICAM-2 and evidence for a third counter-receptor for LFA-1.”J Exp Med174, 253-67.
De Rosa, S. C., et al. “11-color, 13-parameter flow cytometry: Identification of human naive T cells by phenotype, function, and T-cell receptor diversity,”Nat Med7, 245-248. (2001).
Deeths, M. J., and Mescher, M. F. (1999). “ICAM-1 and B7-1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1.”Eur J Immunol29, 45-53.
Devine, L., et al., “Role of LFA-1, ICAM-1, VLA4 and VCAM1- in lymphocyte migration across retinal pigment epithelial monolayers in vitro.”Immunology88, 456-62, 1996.
Diacovo, T. G., et al. (1994). “A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2.”J Clin Invest94, 1243-51.
Dikic, I., et al. (1996). “A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation.”Nature383, 547-50.
Donskov, F., et al. (1996). “Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.”Nat Immun15, 134-146.
Fiering, S. N. et al. “Improved FAGS-Gal: flow cytometric analysis and sorting of viable eukaryotic cells expressing reporter gene constructs.”Cytometry12, 291-301. (1991).
Fine, J. S., and Kruisbeek, A. M. (1991). “The role of LFA-1/ICAM-1 interactions during murine T lymphocyte development.”J Immunol147, 2852-2859.
Geiger, C., et al. (2000). “Cytohesin-1 regulates beta-2 integrin-mediated adhesion through both ARF-GEF function and interaction with LFA-1.”Embo J19, 2525-2536.
Griffioen, A. W., et al. (1996). “Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors.”Cancer Res56, 1111-17.
Griffioen, A. W., et al. (1996). “Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium.”Blood88,667-73.
Helander, T. S., et al. (1996 ). :ICAM-2 redistributed by ezrin as a target for killer cells.Nature382, 265-8.
Hogg, N., et al. (1999). “A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins M
Irish Jonathan M.
Nolan Garry P.
Perez Omar D.
Bozicevic Field & Francis LLP
Field Bret E.
Gabel Gailene R
Scherer David C.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Methods and compositions for risk stratification does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for risk stratification, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for risk stratification will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3956229